Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments
Open accessThe DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.
Abstract
Evidence-based pharmacological treatments are available for first-line treatment of major depressive disorder and for management of inadequate response, however, given the limitations of the evidence base, pharmacological management of MDD still depends on tailoring treatments to the patient.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Current treatment guidelines recommend augmentation strategies after failure of two antidepressants or partial response with a primary antidepressant (Kennedy et al., 2016).”
From Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis (2022) · cites this paper as Kennedy et al., 2016
In the citing paper
“In addition, quetiapine (mean dose,156.74 ± 97.6 mg/day) showed significant benefits for both response and remission rates compared to placebo, which is in accordance with current clinical recommendations for augmentation strategies for MDD (Cleare et al., 2015; Kennedy et al., 2016).”
From Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis (2022) · cites this paper as Kennedy et al., 2016
In the citing paper
“Clinical guidelines such as CANMAT suggest caution regarding the use of stimulant and stimulant like molecules and based on previous meta-analysis (Goss et al., 2013; Kennedy et al., 2016) recommend their utilization as second-third line adjunctive agents.”
From Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis (2022) · cites this paper as Kennedy et al., 2016
In the citing paper
“Despite decades of presence of thyroid hormones amongst the affective disorders’ pharmacopeia, clinical recommendations have varied (Gelenberg et al., 2010; Kennedy et al., 2016).”
From Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis (2022) · cites this paper as Kennedy et al., 2016
In the citing paper
“Our data support current pharmacological augmentation recommendations from several treatment guidelines for depression which recommend the use of AAs as first line agents, specifically the use of aripiprazole and quetiapine (Kennedy et al., 2016; NICE, 2010; Seshadri et al., 2021).”
From Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis (2022) · cites this paper as Kennedy et al., 2016
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Psychosomatic medicine in Germany: more timely than ever
Zipfel, S., Herzog, W., Kruse, J., & Henningsen, P. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447701 · Cited by 2,323
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Self-citationEvaluation of networks of randomized trials
Salanti, G., Higgins, J. P., Ades, A., & Ioannidis, J. P. (2008) · Statistical Methods in Medical Research · doi:10.1177/0962280207080643 · Cited by 1,078
Hicks, J., Bishop, Jr., Sangkuhl, K., Müller, D., Ji, Y., Leckband, S., Leeder, J., Graham, R., Chiulli, D., LLerena, A., et al. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.147 · Cited by 998
Fava, M., Rush, A. J., Alpert, J. E., Balasubramani, G. K., Wisniewski, S. R., Carmin, C. N., Biggs, M. M., Zisook, S., Leuchter, A., Howland, R., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111868 · Cited by 927
Stone, M., Laughren, T., Jones, M. L., Levenson, M., Holland, P. C., Hughes, A., Hammad, T. A., Temple, R., & Rochester, G. (2009) · BMJ · doi:10.1136/bmj.b2880 · Cited by 609 · cited 1×
“The first included data from 372 RCTs comparing 12 antidepressants to placebo and reported a reduced risk of suicidal ideas or acts in those aged 25 to 64 years and a reduced risk of suicidal acts in those older than 65 years.(55) A meta-analysis of fluoxetine and venlafaxine showed no difference in suicidality compar…”
BackgroundMilev, R. V., Giacobbe, P., Kennedy, S. H., Blumberger, D. M., Daskalakis, Z. J., Downar, J., Modirrousta, M., Patry, S., Vila-Rodriguez, F., Lam, R. W., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716660033 · Cited by 586
Self-citationDuloxetine for treating painful neuropathy, chronic pain or fibromyalgia
Lunn, M. P., Hughes, R. A., & Wiffen, P. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007115.pub3 · Cited by 565
Parikh, S. V., Quilty, L. C., Ravitz, P., Rosenbluth, M., Pavlova, B., Grigoriadis, S., Velyvis, V., Kennedy, S. H., Lam, R. W., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659418 · Cited by 562
Self-citationNierenberg, A. A., Fava, M., Trivedi, M. H., Wisniewski, S. R., Thase, M. E., McGrath, P. J., Alpert, J. E., Warden, D., Luther, J. F., Niederehe, G., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1519 · Cited by 559
Nelson, J. C., & Papakostas, G. I. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030312 · Cited by 552
Kennedy, S. H., Lam, R. W., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 525
Self-citationKatona, C., Hansen, T., & Olsen, C. K. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283542457 · Cited by 445
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436 · cited 1×
“Discontinuation symptoms, described by the FINISH mnemonic (flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances, hyperarousal), may be experienced by up to 40% of patients when antidepressants are stopped abruptly.(87,88) These are generally mild and transient, but more severe symptoms have been descr…”
BackgroundMcIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000546 · Cited by 433
Self-citationLam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431 · cited 1×
“The 2009 guidelines recommended that patients maintain treatment with antidepressants for 6 to 9 months after achieving symptomatic remission, while those with risk factors for recurrence extend antidepressant treatment to 2 years or more.(82) New evidence continues to support this recommendation for antidepressant ma…”
Self-citationTreatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
McIntyre, R. S., Filteau, M.-J., Martin, L., Patry, S., Carvalho, A., Cha, D. S., Barakat, M., & Miguelez, M. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.043 · Cited by 421 · cited 2×
“, <25% reduction) to the initial treatment, clinicians should ensure the treatment is optimized.(90,91) There is substantial evidence that many patients receive subtherapeutic doses and/or inadequate duration of treatment, and up to 20% may have poor adherence.”
BackgroundSelf-citationBerlim, M. T., & Turecki, G. (2007) · The Canadian Journal of Psychiatry · doi:10.1177/070674370705200108 · Cited by 412 · cited 1×
“, <25% reduction) to the initial treatment, clinicians should ensure the treatment is optimized.(90,91) There is substantial evidence that many patients receive subtherapeutic doses and/or inadequate duration of treatment, and up to 20% may have poor adherence.”
BackgroundMcKnight, P. E., & Kashdan, T. B. (2009) · Clinical Psychology Review · doi:10.1016/j.cpr.2009.01.005 · Cited by 400 · cited 1×
“Systematic reviews show that functional outcomes are only modestly correlated with symptom outcomes, and functional improvement may lag behind symptom improvement.(51) Few studies of antidepressants assess functional outcomes.”
BackgroundRush, A. J., Trivedi, M. H., Stewart, J. W., Nierenberg, A. A., Fava, M., Kurian, B. T., Warden, D., Morris, D. W., Luther, J. F., Husain, M. M., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111645 · Cited by 372
Gartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K., Lux, L., Van Noord, M., Mager, U., Thieda, P., Gaynes, B. N., Wilkins, T., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-11-201112060-00009 · Cited by 355 · cited 3×
“The differences in response rates were modest, ranging from 5% to 6%.(46) A network meta-analysis of only head-to-head trials found that agomelatine, escitalopram, mirtazapine, and venlafaxine were superior to fluoxetine.”
BackgroundInfluentialKetamine administration in depressive disorders: a systematic review and meta-analysis
Fond, G., Loundou, A., Rabu, C., Macgregor, A., Lançon, C., Brittner, M., Micoulaud-Franchi, J.-A., Richieri, R., Courtet, P., Abbar, M., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3664-5 · Cited by 339
Suppes, T., Silva, R., Cucchiaro, J., Mao, Y., Targum, S., Streicher, C., Pikalov, A., & Loebel, A. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15060770 · Cited by 322
Blier, P., Ward, H. E., Tremblay, P., Laberge, L., Hébert, C., & Bergeron, R. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020186 · Cited by 316
Self-citationRosenblat, J. D., Kakar, R., & McIntyre, R. S. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv082 · Cited by 315 · cited 1×
“In a metaanalysis (17 studies, N 1⁄4 3653) reviewing the cognitive effects of antidepressants based on neuropsychological tests, vortioxetine had the largest effects on processing speed, executive control, and cognitive control, while duloxetine had the largest effects on delayed recall.(17) The quality of these data…”
BackgroundSelf-citationMahableshwarkar, A. R., Zajecka, J., Jacobson, W., Chen, Y., & Keefe, R. S. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.52 · Cited by 307
Gibbons, R. D., Brown, C. H., Hur, K., Davis, J. M., & Mann, J. J. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2048 · Cited by 291
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Papakostas, G. I., Fava, M., & Thase, M. E. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.08.010 · Cited by 284
The use of ketamine as an antidepressant: a systematic review and meta‐analysis
Coyle, C. M., & Laws, K. R. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2475 · Cited by 279 · cited 1×
“However, ketamine is associated with psychotomimetic adverse effects, carries potential for abuse, and still has very limited data on safety and efficacy with longer term use.(126,129,130) CANMAT considers ketamine an experimental treatment and recommends its use be limited to academic depression treatment centres.”
BackgroundBarbui, C., Esposito, E., & Cipriani, A. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.081514 · Cited by 275
Spielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001403 · Cited by 275
Vieweg, W. V. R., Hasnain, M., Howland, R. H., Hettema, J. M., Kogut, C., Wood, M. A., & Pandurangi, A. K. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.12.002 · Cited by 270
Self-citationKantrowitz, J., Citrome, L., & Javitt, D. (2009) · CNS Drugs · doi:10.2165/00023210-200923080-00001 · Cited by 260
MacQueen, G. M., Frey, B. N., Ismail, Z., Jaworska, N., Steiner, M., Lieshout, R. J. V., Kennedy, S. H., Lam, R. W., Milev, R. V., Parikh, S. V., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659276 · Cited by 248
Self-citationAnglin, R., Yuan, Y., Moayyedi, P., Tse, F., Armstrong, D., & Leontiadis, G. I. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.82 · Cited by 234
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
Dale, E., Bang-Andersen, B., & Sánchez, C. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.03.011 · Cited by 234
The role of ketamine in treatment-resistant depression: A systematic review
Serafini, G., Howland, R., Rovedi, F., Girardi, P., & Amore, M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140619204251 · Cited by 234 · cited 1×
“However, ketamine is associated with psychotomimetic adverse effects, carries potential for abuse, and still has very limited data on safety and efficacy with longer term use.(126,129,130) CANMAT considers ketamine an experimental treatment and recommends its use be limited to academic depression treatment centres.”
BackgroundKetamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression
Wan, L.-B., Levitch, C. F., Perez, A. M., Brallier, J. W., Iosifescu, D. V., Chang, L. C., Foulkes, A., Mathew, S. J., Charney, D. S., & Murrough, J. W. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08852 · Cited by 231
Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants
Khoo, A. L., Zhou, H. J., Teng, M., Lin, L., Zhao, Y. J., Soh, L. B., Mok, Y. M., Lim, B. P., & Gwee, K. P. (2015) · CNS Drugs · doi:10.1007/s40263-015-0267-6 · Cited by 228
Citrome, L. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02885.x · Cited by 228
Laughren, T. P., Gobburu, J., Temple, R. J., Unger, E. F., Bhattaram, A., Dinh, P. V., Fossom, L., Hung, H. M. J., Klimek, V., Lee, J. E., et al. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11r06984 · Cited by 226
Ibrahim, L., DiazGranados, N., Jolkovsky, L., Brutsche, N., Luckenbaugh, D. A., Herring, W. J., Potter, W. Z., & Zarate, C. A. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d70d6 · Cited by 220
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218 · cited 1×
“A meta-analysis found significant benefit of antidepressants over placebo in maintenance studies of 1 to 12 months (72 trials, N 1⁄4 14450) and 12 months (35 trials, N 1⁄4 7253).(83) Similarly, a review of all 16 maintenance RCTs (N > 4000) submitted to the Food and Drug Administration (FDA) found a 2-fold difference…”
BackgroundO'Brien, F. E., Dinan, T. G., Griffin, B. T., & Cryan, J. F. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01557.x · Cited by 215
Jiang, H.-Y., Chen, H.-Z., Hu, X.-J., Yu, Z.-H., Yang, W., Deng, M., Zhang, Y.-H., & Ruan, B. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.06.021 · Cited by 213
Ramasubbu, R., Taylor, V. H., Samaan, Z., Sockalingham, S., Li, M., Patten, S., Rodin, G., Schaffer, A., Beaulieu, S., & McIntyre, R. S. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400110 · Cited by 206
Self-citationHieronymus, F., Emilsson, J. F., Nilsson, S., & Eriksson, E. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.53 · Cited by 201
Zhou, X., Keitner, G. I., Qin, B., Ravindran, A. V., Bauer, M., Del Giovane, C., Zhao, J., Liu, Y., Fang, Y., Zhang, Y., et al. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv060 · Cited by 197
Self-citationRendleman, R., & Walkup, J. T. (2012) · Swaiman's Pediatric Neurology · doi:10.1016/b978-1-4377-0435-8.00049-4 · Cited by 196
PRESKORN, S., MACALUSO, M., MEHRA, D. V., ZAMMIT, G., MOSKAL, J. R., & BURCH, R. M. (2015) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000462606.17725.93 · Cited by 193
Escitalopram versus other antidepressive agents for depression
Cipriani, A., Santilli, C., Furukawa, T. A., Signoretti, A., Nakagawa, A., McGuire, H., Churchill, R., & Barbui, C. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006532.pub2 · Cited by 190
Zhou, X., Ravindran, A. V., Qin, B., Del Giovane, C., Li, Q., Bauer, M., Liu, Y., Fang, Y., da Silva, T., Zhang, Y., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14r09204 · Cited by 189 · cited 2×
“A network meta-analysis of RCTs (48 trials, N1⁄4 6654) examined the comparative adjunctive effects of aripiprazole, bupropion, buspirone, lamotrigine, lithium, methylphenidate, olanzapine, pindolol, quetiapine, risperidone, and thyroid hormone with each other and with placebo.(102) Only aripiprazole, lithium, quetiapi…”
BackgroundSelf-citationDifferential efficacy of escitalopram and nortriptyline on dimensional measures of depression
Uher, R., Maier, W., Hauser, J., Marušič, A., Schmael, C., Mors, O., Henigsberg, N., Souery, D., Placentino, A., Rietschel, M., et al. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.057554 · Cited by 186
Self-citationThase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Augustine, C., Zhang, P., McQuade, R. D., Carson, W. H., Nyilas, M., Sanchez, R., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09688 · Cited by 182
Na, K.-S., Lee, K. J., Lee, J. S., Cho, Y. S., & Jung, H.-Y. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.09.006 · Cited by 176
Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial
Arnow, B. A., Blasey, C., Williams, L. M., Palmer, D. M., Rekshan, W., Schatzberg, A. F., Etkin, A., Kulkarni, J., Luther, J. F., & Rush, A. J. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14020181 · Cited by 175 · cited 1×
“Large trials examining response with DSM-IV specifiers (melancholic, atypical, anxious) found no differences in efficacy between escitalopram, sertraline, and venlafaxine XR or between escitalopram and nortriptyline.(24,25) The US STAR*D study also did not find differences in remission rates with citalopram in atypica…”
Second-generation antipsychotics for major depressive disorder and dysthymia
Komossa, K., Depping, A. M., Gaudchau, A., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008121.pub2 · Cited by 171
Hasnain, M., & Vieweg, W. V. R. (2014) · CNS Drugs · doi:10.1007/s40263-014-0196-9 · Cited by 170
Self-citationSerotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome
Häuser, W., Urrútia, G., Tort, S., Üçeyler, N., & Walitt, B. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010292 · Cited by 166
Thase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Zhang, P., McQuade, R. D., Nyilas, M., Carson, W. H., Sanchez, R., & Eriksson, H. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09689 · Cited by 165
Trivedi, M. H., Rush, A. J., Gaynes, B. N., Stewart, J. W., Wisniewski, S. R., Warden, D., Ritz, L., Luther, J. F., Stegman, D., DeVeaugh-Geiss, J., et al. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301390 · Cited by 163
Wu, Q. F., Bencaz, A. F., Hentz, J. G., & Crowell, M. D. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1778-8 · Cited by 162
Blier, P., Gobbi, G., Turcotte, J. E., de Montigny, C., Boucher, N., Hébert, C., & Debonnel, G. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.01.015 · Cited by 161
Self-citationReichenpfader, U., Gartlehner, G., Morgan, L. C., Greenblatt, A., Nussbaumer, B., Hansen, R. A., Van Noord, M., Lux, L., & Gaynes, B. N. (2014) · Drug Safety · doi:10.1007/s40264-013-0129-4 · Cited by 160
Clinically Significant Drug Interactions with Newer Antidepressants
Spina, E., Trifirò, G., & Caraci, F. (2012) · CNS Drugs · doi:10.2165/11594710-000000000-00000 · Cited by 160
Linde, K., Kriston, L., Rucker, G., Jamil, S., Schumann, I., Meissner, K., Sigterman, K., & Schneider, A. (2015) · The Annals of Family Medicine · doi:10.1370/afm.1687 · Cited by 151
von Wolff, A., Hölzel, L. P., Westphal, A., Härter, M. C., & Kriston, L. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.06.007 · Cited by 141
Nelson, J. C., Baumann, P., Delucchi, K., Joffe, R. T., & Katona, C. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.05.053 · Cited by 141
Coupland, C., Dhiman, P., Barton, G., Morriss, R., Arthur, A., Sach, T., & Hippisley-Cox, J. (2011) · Health Technology Assessment · doi:10.3310/hta15280 · Cited by 141
Citrome, L. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12350 · Cited by 140
Role of Lithium Augmentation in the Management of Major Depressive Disorder
Bauer, M., Adli, M., Ricken, R., Severus, E., & Pilhatsch, M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0152-8 · Cited by 139
Pharmacological treatment for psychotic depression
Wijkstra, J., Lijmer, J., Burger, H., Cipriani, A., Geddes, J., & Nolen, W. A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004044.pub4 · Cited by 137
Relationship between use of antidepressants and risk of fractures: a meta-analysis
Rabenda, V., Nicolet, D., Beaudart, C., Bruyère, O., & Reginster, J.-Y. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2015-9 · Cited by 135
Bond, D. J., Hadjipavlou, G., Lam, R. W., McIntyre, R. S., Beaulieu, S., Schaffer, A., & Weiss, M. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400104 · Cited by 133
Self-citationGoss, A. J., Kaser, M., Costafreda, S. G., Sahakian, B. J., & Fu, C. H. Y. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08560 · Cited by 133
McGirr, A., Berlim, M. T., Bond, D. J., Neufeld, N. H., Chan, P. Y., Yatham, L. N., & Lam, R. W. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.01.003 · Cited by 127
Self-citationBoulenger, J.-P., Loft, H., & Florea, I. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112441866 · Cited by 127 · cited 1×
“A relapse-prevention study showed superiority of vortioxetine over placebo.(18) Comparator studies are published for vortioxetine and agomelatine, duloxetine, and venlafaxine.”
BackgroundCarvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123 · cited 1×
“The value of switching between classes or within classes of antidepressants remains controversial.(100) A previous meta-analysis (4 studies, N 1⁄4 1496) found a modest, but statistically significant, remission advantage for patients on an SSRI switched to an antidepressant in a different class (bupropion, mirtazapine,…”
BackgroundSelf-citationEom, C.-S., Lee, H.-K., Ye, S., Park, S. M., & Cho, K.-H. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1554 · Cited by 123
Ravindran, A. V., Kennedy, S. H., O'Donovan, M. C., Fallu, A., Camacho, F., & Binder, C. E. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0112 · Cited by 119 · cited 1×
“A few studies have addressed residual symptoms, such as fatigue or sexual dysfunction.(134,135) However, there is no consistent evidence to support specific adjunctive agents to target specific residual symptoms or side effects.”
BackgroundSelf-citationKriston, L., von Wolff, A., Westphal, A., Hölzel, L. P., & Härter, M. (2014) · Depression and Anxiety · doi:10.1002/da.22236 · Cited by 119 · cited 3×
“The network meta-analysis also identified differences in effects between combined psychotherapy þ medication and medication-only studies in dysthymia studies compared to studies of chronic MDD, suggesting that the new diagnosis of PDD may not have homogeneous treatment response.(136) Although there are positive result…”
BackgroundResultInfluentialBaune, B. T., & Renger, L. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.05.013 · Cited by 115 · cited 2×
“Another systematic review (35 studies) examined the relationships between antidepressants, cognitive dysfunction, and functional ability.(31) Antidepressants were generally associated with improvement in cognitive domains, but there was no conclusive evidence that improved cognition led to improved overall functioning.”
BackgroundBorges, S., Chen, Y.-F., Laughren, T. P., Temple, R., Patel, H. D., David, P. A., Mathis, M., Unger, E., Yang, P., & Khin, N. A. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08722 · Cited by 109
Lieberman, J. A., Greenhouse, J. B., Hamer, R. M., Krishnan, K. R. R., Nemeroff, C. B., Sheehan, D. V., Thase, M. E., & Keller, M. B. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300571 · Cited by 109
Renoir, T. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00045 · Cited by 107
Lam, R. W. M., Kennedy, S. H., Parikh, S. V., MacQUEEN, G. M., Milev, R. V., Ravindran, A. V., & the CANMAT Depression Work Group (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659061 · Cited by 107
Self-citationMcGrath, P. J., Khan, A. Y., Trivedi, M. H., Stewart, J. W., Morris, D. W., Wisniewski, S. R., Miyahara, S., Nierenberg, A. A., Fava, M., & Rush, A. J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n1201 · Cited by 105
(2012) · PubMed · Cited by 100
Self-citationEmerging drugs for major depressive disorder
Connolly, K. R., & Thase, M. E. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.660146 · Cited by 96
Clinically Significant Drug Interactions with Atypical Antipsychotics
Kennedy, W. K., Jann, M. W., & Kutscher, E. C. (2013) · CNS Drugs · doi:10.1007/s40263-013-0114-6 · Cited by 95 · cited 1×
“However, there is no consistent evidence of clinically relevant P-glycoprotein interactions with antidepressants or antipsychotics.(74,75) Although not a pharmacokinetic drug-drug interaction, serotonin syndrome and/or hypertensive crisis can occur when serotonergic or sympathomimetic drugs are combined with MAO inhib…”
BackgroundCusin, C., Iovieno, N., Iosifescu, D. V., Nierenberg, A. A., Fava, M., Rush, A. J., & Perlis, R. H. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08093 · Cited by 93
Genes, Environment, and Individual Differences in Responding to Treatment for Depression
Uher, R. (2011) · Harvard Review of Psychiatry · doi:10.3109/10673229.2011.586551 · Cited by 92
Self-citationKudlow, P., McIntyre, R., & Lam, R. (2014) · CNS Drugs · doi:10.1007/s40263-014-0171-5 · Cited by 84
Self-citationSafarinejad, M. R. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109351966 · Cited by 80
Drozda, K., Müller, D. J., & Bishop, J. R. (2014) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1398 · Cited by 78
Self-citationGaynes, B. N., Dusetzina, S. B., Ellis, A. R., Hansen, R. A., Farley, J. F., Miller, W. C., & Stürmer, T. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823f705d · Cited by 78
Cooper-Kazaz, R., & Lerer, B. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008206 · Cited by 78
Madhoo, M., Keefe, R. S., Roth, R. M., Sambunaris, A., Wu, J., Trivedi, M. H., Anderson, C. S., & Lasser, R. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.334 · Cited by 74
Repeated S‐ketamine Infusions in Therapy Resistant Depression: A Case Series
Segmiller, F. M., Rüther, T., Linhardt, A., Padberg, F., Berger, M., Pogarell, O. M., Möller, H., Kohler, C., & Schüle, C. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.122 · Cited by 74
Rocha, F. L., Fuzikawa, C., Riera, R., & Hara, C. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318248581b · Cited by 73
Patkar, A., Gilmer, W., Pae, C.-U., Vöhringer, P. A., Ziffra, M., Pirok, E., Mulligan, M., Filkowski, M. M., Whitham, E. A., Holtzman, N. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034757 · Cited by 73
Brandl, E. J., Tiwari, A. K., Zhou, X., Deluce, J. E., Kennedy, J. L., Müller, D., & Richter, M. A. (2013) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.12 · Cited by 72
Self-citationPae, C.-U., Wang, S.-M., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Serretti, A. (2015) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.140120 · Cited by 71
McIntyre, R. S., Rosenbluth, M., Ramasubbu, R., Bond, D. J., Taylor, V. H., Beaulieu, S., & Schaffer, A. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400209 · Cited by 70
Self-citationManagement of Treatment-Resistant Depression
Keitner, G. I., & Mansfield, A. K. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.11.004 · Cited by 70
Abadie, D., Rousseau, V., Logerot, S., Cottin, J., Montastruc, J., & Montastruc, F. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000344 · Cited by 70
Ramasubbu, R., Beaulieu, S., Taylor, V. H., Schaffer, A., & McIntyre, R. S. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400109 · Cited by 69
Self-citationThaler, K. J., Morgan, L. C., Noord, M. V., Gaynes, B. N., Hansen, R. A., Lux, L. J., Krebs, E. E., Lohr, K. N., & Gartlehner, G. (2012) · Depression and Anxiety · doi:10.1002/da.21951 · Cited by 69
Veselinović, T., Paulzen, M., & Gründer, G. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.853448 · Cited by 69
Alberti, S., Chiesa, A., Andrisano, C., & Serretti, A. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000329 · Cited by 65
Do atypical features affect outcome in depressed outpatients treated with citalopram?
Stewart, J. W., McGrath, P. J., Fava, M., Wisniewski, S. R., Zisook, S., Cook, I., Nierenberg, A. A., Trivedi, M. H., Balasubramani, G. K., Warden, D., et al. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000182 · Cited by 64
Lam, R. W., Parikh, S. V., Michalak, E. E., Dewa, C. S., & Kennedy, S. H. (2015) · Annals of Clinical Psychiatry · doi:10.1177/104012371502700209 · Cited by 62 · cited 1×
“CANMAT recommendations for assessment of functional outcomes highlighted the critical impact of depressive symptoms on social, occupational, and physical functioning and that recovery from depression involves both relief of symptoms and improvement of functioning.(50) Systematic reviews show that functional outcomes a…”
BackgroundSelf-citationTrivedi, M. H., Thase, M. E., Osuntokun, O., Henley, D. B., Case, M., Watson, S. B., Campbell, G. M., & Corya, S. A. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04064 · Cited by 62
Papakostas, G. I., Fava, M., Baer, L., Swee, M. B., Jaeger, A., Bobo, W. V., & Shelton, R. C. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14101251 · Cited by 58
(2015) · Europe PMC (PubMed Central) · Cited by 58
Trivedi, M. H., Cutler, A. J., Richards, C., Lasser, R., Geibel, B. B., Gao, J., Sambunaris, A., & Patkar, A. A. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08360 · Cited by 58
Ramsberg, J., Asseburg, C., & Henriksson, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042003 · Cited by 57
Corp, S. A., Gitlin, M. J., & Altshuler, L. L. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08851 · Cited by 56 · cited 1×
“, methylphenidate) have only negative studies.(125) Several meta-analyses have shown that single doses of intravenous ketamine, which preferentially target N-methyl-D-aspartate (NMDA) receptors, have rapid antidepressant effects in TRD.”
BackgroundMajd, M., Hashemian, F., Hosseini, S., Shariatpanahi, M. V., & Sharifi, A. (2015) · Iranian journal of pharmaceutical research · doi:10.22037/ijpr.2015.1637 · Cited by 55
Duration of Initial Antidepressant Treatment and Subsequent Relapse of Major Depression
Baldessarini, R. J., Lau, W. K., Sim, J., Sum, M. Y., & Sim, K. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000263 · Cited by 52
Combination antidepressant therapy for major depressive disorder: Speed and probability of remission
Stewart, J. W., McGrath, P. J., Blondeau, C., Deliyannides, D. A., Hellerstein, D. J., Norris, S., Amat, J., Pilowsky, D. J., Tessier, P., Laberge, L., et al. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.12.001 · Cited by 50
Self-citationWithdrawal of Generic Budeprion for Nonbioequivalence
Woodcock, J., Khan, M. A., & Yu, L. X. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1212969 · Cited by 48
FINISH: Remembering the Discontinuation Syndrome
Berber, M. J. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0509b · Cited by 47
Gilmer, W. S., Gollan, J. K., Wisniewski, S. R., Howland, R. H., Trivedi, M. H., Miyahara, S., Fleck, J., Thase, M. E., Alpert, J. E., Nierenberg, A. A., et al. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0807 · Cited by 46
Carpenter, D. J., Fong, R., Kraus, J. E., Davies, J. T., Moore, C., & Thase, M. E. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04927blu · Cited by 42
Han, C., Wang, S., Kwak, K., Won, W.-Y., Lee, H.-Y., Chang, C., Tang, T. C., & Pae, C. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.04.020 · Cited by 41
Wen, X. J., Wang, L. M., Liu, Z. L., Huang, A., Liu, Y. Y., & Hu, J. Y. (2014) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20143672 · Cited by 41
Nakajima, S., Uchida, H., Suzuki, T., Watanabe, K., Hirano, J., Yagihashi, T., Takeuchi, H., Abe, T., Kashima, H., & Mimura, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.08.008 · Cited by 40
Beaulieu, S., Saury, S., Sareen, J., Tremblay, J., Schütz, C. G., McIntyre, R. S., & Schaffer, A. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400105 · Cited by 38
Self-citationA review of current evidence for vilazodone in major depressive disorder
Wang, S.-M., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2013) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2013.794245 · Cited by 37
Trivedi, M. H., Dunner, D. L., Kornstein, S. G., Thase, M. E., Zajecka, J. M., Rothschild, A. J., Friedman, E. S., Shelton, R. C., Keller, M. B., Kocsis, J. H., et al. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.04.011 · Cited by 36
Berber, M. J. (1998) · PubMed · Cited by 32
Early Switch Strategy in Patients With Major Depressive Disorder: A Double-Blind, Randomized Study
Romera, I., Pérez, V., Menchón, J. M., Schacht, A., Papen, R., Neuhauser, D., Abbar, M., Svanborg, P., & Gilaberte, I. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d9958 · Cited by 32
Hellerstein, D. J., & Flaxer, J. M. (2015) · Core evidence · doi:10.2147/ce.s54075 · Cited by 30
Kamenov, K., Cabello, M., Coenen, M., & Ayuso‐Mateos, J. L. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.08.035 · Cited by 30
Rational Use of Generic Psychotropic Drugs
Carbon, M., & Correll, C. U. (2013) · CNS Drugs · doi:10.1007/s40263-013-0045-2 · Cited by 27
Montgomery, S., Gommoll, C., Chen, C., & Greenberg, W. M. (2014) · CNS Spectrums · doi:10.1017/s1092852914000273 · Cited by 27
Liu, Y., Zhou, X., Zhu, D., Chen, J., Qin, B., Zhang, Y., Wang, X., Yang, D., Meng, H., Luo, Q., et al. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2465 · Cited by 26 · cited 1×
“There was no significant benefit for pindolol versus placebo in combination with SSRI therapy and no differences in tolerability or safety between the 2 groups.(131) Pindolol is not recommended as an adjunct treatment.”
Background(2014) · Europe PMC (PubMed Central) · Cited by 24
Galling, B., Ferrer, A. C., Daou, M. A. Z., Sangroula, D., Hagi, K., & Correll, C. U. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1085970 · Cited by 24
Dell’Osso, B. M., & Ketter, T. A. (2013) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283639015 · Cited by 20
Nußbaumer-Streit, B., Morgan, L. C., Reichenpfader, U., Greenblatt, A. M., Hansen, R. A., Noord, M. V., Lux, L. J., Gaynes, B. N., & Gartlehner, G. (2014) · CNS Drugs · doi:10.1007/s40263-014-0169-z · Cited by 18
Quiroz, J. A., Tamburri, P. A., Deptula, D., Banken, L., Beyer, U., da Fontoura, P. P., & Santarelli, L. (2014) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(14)70748-5 · Cited by 17
Kronstein, P. D., Ishida, E., Khin, N. A., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14r09699 · Cited by 12
Rosenbluth, M., MacQueen, G., McIntyre, R. S., Beaulieu, S., & Schaffer, A. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400106 · Cited by 12
Self-citationAntidepressant Nonadherence in Routine Clinical Settings Determined From Discarded Blood Samples
Roberson, A. M., Castro, V. M., Cagan, A., & Perlis, R. H. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09612 · Cited by 11
McIntyre, R. S., Schaffer, A., & Beaulieu, S. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400101 · Cited by 11
Self-citationPramipexole augmentation in treatment-resistant major depressive disorder
Pae, C. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.864556 · Cited by 8
Schaffer, A., McIntosh, D., Goldstein, B. I., Rector, N. A., McIntyre, R. S., Beaulieu, S., Swinson, R., & Yatham, L. N. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400103 · Cited by 7
Self-citation
Research works printed but not linked: 1
- Rush AJ, Warden D, Wisniewski SR, . STAR*D: revising conventional wisdom. CNS Drugs. 2009;23:627–647.
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationMarx, W., Penninx, B. W. J. H., Solmi, M., Furukawa, T. A., Firth, J., Carvalho, A. F., & Berk, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00454-1 · Cited by 768
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
Self-citationDepression in the Primary Care Setting
Park, L. T., & Zarate, C. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmcp1712493 · Cited by 458
Maj, M., Stein, D. J., Parker, G., Zimmerman, M., Fava, G. A., De Hert, M., Demyttenaere, K., McIntyre, R. S., Widiger, T., & Wittchen, H. (2020) · World Psychiatry · doi:10.1002/wps.20771 · Cited by 435
Self-citation
Metadata
- Authors
- Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., McInerney, S. J., McIntosh, D., Milev, R. V., Müller, D. J., Parikh, S. V., Pearson, N. L., Ravindran, A. V., Uher, R., & the CANMAT Depression Work Group
- Affiliations
- University of Toronto (CA)
- University of British Columbia (CA)
- Department of Psychiatry, L’Université de Montréal, Montréal, Quebec
- McGill University (CA)
- University of Ottawa (CA)
- Memorial University of Newfoundland (CA)
- University of Calgary (CA)
- Queen's University (CA)
- Canadian Pharmacists Association (CA)
- Dalhousie University (CA)
- ORCID
- Venue
- The Canadian Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2016-08-11
- Volume
- 61
- Issue
- 9
- Pages
- 540-560
- ISSN
- 0706-7437 (ISSN-L)
- 1497-0015
- PMC
- PMC4994790
- OpenAlex
- W2478017657
- Cited by
- 1,181
- References
- 152
- Citations by year
- 2026: 81 · 2025: 117 · 2024: 183 · 2023: 151 · 2022: 148 · 2021: 137 · 2020: 146 · 2019: 101 · 2018: 69 · 2017: 41 · 2016: 5
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Update notices
- correction (2017-05-19)
- Open access
- bronze
- doi.org
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- The Canadian Journal of Psychiatry (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- International Society for Bipolar Disorders
- Canadian Network for Mood and Anxiety Treatments
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- major depressive disorder, antidepressant treatment, second-generation antidepressants, antidepressant selection, drug-drug interactions, maintenance therapy, inadequate response to antidepressants, treatment-resistant depression, antidepressant switching, adjunctive therapy, measurement-based care, personalized treatment
- MeSH terms
- Antidepressive Agents, Canada, Major Depressive Disorder, Humans, Societies, Medical, Practice Guidelines as Topic, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.